State of Alaska Department of Revenue Raises Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

State of Alaska Department of Revenue lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 7.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,035 shares of the biotechnology company’s stock after acquiring an additional 750 shares during the period. State of Alaska Department of Revenue’s holdings in Sarepta Therapeutics were worth $1,378,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of SRPT. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Sarepta Therapeutics by 100.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,996 shares of the biotechnology company’s stock worth $647,000 after buying an additional 2,504 shares during the period. Commonwealth Equity Services LLC grew its stake in Sarepta Therapeutics by 8.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 5,243 shares of the biotechnology company’s stock valued at $679,000 after purchasing an additional 418 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Sarepta Therapeutics by 111.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 90,945 shares of the biotechnology company’s stock valued at $12,131,000 after purchasing an additional 47,895 shares during the period. Nordea Investment Management AB increased its holdings in shares of Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after purchasing an additional 33,711 shares during the period. Finally, Central Pacific Bank Trust Division acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth about $414,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Down 2.2 %

Shares of SRPT stock opened at $123.29 on Monday. Sarepta Therapeutics, Inc. has a fifty-two week low of $75.69 and a fifty-two week high of $173.25. The firm has a market capitalization of $11.76 billion, a P/E ratio of 273.98 and a beta of 0.81. The stock’s fifty day moving average is $127.42 and its two-hundred day moving average is $132.67. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the firm posted ($0.27) earnings per share. Research analysts expect that Sarepta Therapeutics, Inc. will post 1.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Cantor Fitzgerald reissued a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 20th. Barclays lowered their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Raymond James reaffirmed an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Insider Activity

In related news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.